Perrigo

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Perrigo reports strong Q1 growth, faces challenges in product shortages

Perrigo's Q1 2023 performance showcased growth and margin expansion, with a focus on operational excellence. The company faces challenges with product shortages and declining national brand volumes but sees opportunities in pricing increases and supply chain optimization. By leveraging strengths in private label growth and strategic initiatives, Perrigo aims to deliver on guidance for the year.

Perrigo reports strong Q2 performance, eyes Opill launch success

Perrigo's Q2 2023 earnings call highlighted strong financial performance, strategic strengths, key challenges, and growth opportunities. The company is focused on sustainable growth, market differentiation, and leveraging its capabilities for success in the industry.

Perrigo reports solid Q3 earnings, navigates challenges for future growth

Perrigo's Q3 performance showcased growth in net sales and margin expansion, despite challenges in certain product segments. The company remains focused on margin improvement, supply chain optimization, and growth initiatives for future success. With revised outlooks and ongoing strategic efforts, Perrigo aims to navigate challenges and capitalize on growth opportunities.

Perrigo reports robust Q4 earnings, focuses on growth initiatives

Perrigo's Q4 2023 earnings call showcased strong financial performance, with notable growth in net sales and margins.
While facing challenges in its infant formula business, the company outlined remediation plans and expects recovery in the second half of 2024.
Opportunities lie in the launch of Opill, Project Energise, and a focus on strengthening the infant formula business.
Perrigo aims to drive growth by executing strategic initiatives and providing more clarity on growth perspectives during an upcoming Investor Day.

Perrigo reports Q1 challenges, Opill success, and growth opportunities

Perrigo faced challenges in net sales due to infant formula actions but showed strength in innovation and store brands.
Opportunities lie in adapting to retailer inventory changes and expected gross margin improvement in Q2.
The company remains on track to meet 2024 commitments with progress in infant formula recovery and successful product launches.
Analysts focused on infant formula progress, Opill revenue potential, and portfolio refinements during the call.

Perrigo reports Q2 resilience amidst challenges, eyes growth opportunities

Perrigo faced challenges in Q2 2024 with a decline in organic net sales, primarily due to infant formula and certain category sales. Despite this, the company showed resilience with growth in operating income and a focus on core segments. Opportunities lie in recovering share, enhancing marketing, and the potential for infant formula recovery.

Perrigo reports robust Q3 earnings, focuses on efficiency and growth

Perrigo's Q3 performance reflects a resilient financial position, marked by strong EPS growth and operational efficiency gains through cost-saving initiatives.
While facing challenges in net sales decline, the company's strategic focus on core business stabilization and efficiency improvements bodes well for long-term growth.
With a commitment to financial targets, Perrigo is poised to capitalize on opportunities for revenue diversification and market expansion, supported by a strengthened operational foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Mr. Eduardo G. Bezerra named EVP, Chief Financial Officer Mr.

PERRIGO ANNOUNCES PLANNED LEADERSHIP SUCCESSION

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Perrigo (PRGO) Q1 Earnings Expected to Decline

DUBLIN , May 2, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products , today announced that on April 29, 2022 it completed the previously announced acquisition of Héra SAS ("HRA") for €1.8 billion, or approximately $1.9 billion based on current exchange rates, in cash, accelerating its position as a leading global consumer self-care company. Perrigo President and CEO, Murray S.

PERRIGO COMPLETES THE ACQUISITION OF HRA PHARMA

DUBLIN , April 28, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the closing date of the previously announced acquisition of Héra SAS ("HRA" or "HRA Pharma") is expected to occur on April 29, 2022, subject to the satisfaction or waiver of the remaining closing conditions set forth in the securities sale agreement. About Perrigo   Perrigo Company plc (NYSE: PRGO) is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

PERRIGO ANNOUNCES EXPECTED TRANSACTION CLOSE DATE OF HRA PHARMA

DUBLIN , April 27, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. The Company will also host a conference call beginning at 8:30 A.M.

PERRIGO TO RELEASE FIRST QUARTER 2022 FINANCIAL RESULTS ON MAY 11, 2022

Comcast

Hanesbrands

Starbucks

Stanley Black & Decker

U.S. equities vacillated between gains and losses for the week ending April 22, 2022, driven by the release of corporate earnings and the Federal Reserve's interest rate guidance. Strong reports from the airline industry suggest the economy will remain supported by roaring demand for services.

5 Laggards For The Weekend

DUBLIN , April 20, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that it closed its previously announced senior secured credit facilities. The new facilities consist of (i) a $1.0 billion five-year revolving credit facility (the "New Revolving Facility"), (ii) a $500 million five-year term loan A facility (the "New Term Loan A Facility"), and (iii) a $1.1 billion seven-year term loan B facility (the "New Term Loan B Facility" and, together with the New Term Loan A Facility, the "New Term Loan Facilities," and the New Term Loan Facilities together with the New Revolving Facility, the "New Senior Secured Credit Facilities").

PERRIGO ANNOUNCES CLOSING OF $2.6 BILLION SENIOR SECURED CREDIT FACILITIES

DUBLIN, April 4, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Quality, Affordable Self-Care Products, today announced that it has launched a private offering (the "Offering") of $500 million aggregate principal amount of senior notes due 2030 (the "Notes"), subject to market and other conditions, through its indirect wholly-owned subsidiaries, Perrigo Investments, LLC and Perrigo Investments Capital, Inc. (together, the "Issuers"). The Company intends to use the net proceeds from the Offering, together with cash on hand and borrowings under the term loan facilities of its previously-announced syndication of new senior secured credit facilities, to finance the proposed acquisition (the "Acquisition") of Héra SAS ("Héra") and to refinance certain existing indebtedness of the Company and its subsidiaries, including its outstanding term loan facility, its 4.00% Senior Notes due 2023 and its 5.1045% Guaranteed Senior Notes due 2023.

PERRIGO ANNOUNCES LAUNCH OF PRIVATE NOTES OFFERING

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Why Is Perrigo (PRGO) Up 0.9% Since Last Earnings Report?

DUBLIN , March 28, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Quality, Affordable Self-Care Products, today announced that it has launched the syndication of new senior secured credit facilities expected to consist of (i) a $1,000 million five-year revolving credit facility (the "New Revolving Facility") and (ii) a $300 million five-year term loan A facility and a $800 million seven-year term loan B facility (the "New Term Loan Facilities" and, together with the New Revolving Facility, the "New Senior Secured Credit Facilities") through its indirect wholly-owned subsidiary, Perrigo Investments, LLC.  The New Senior Secured Credit Facilities will be guaranteed by the Company and certain wholly-owned subsidiaries of the Company.

PERRIGO ANNOUNCES LAUNCH OF SYNDICATION OF NEW SENIOR SECURED CREDIT FACILITIES

DUBLIN, March 24, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced the planned retirement of Ray Silcock, Executive Vice President and Chief Financial Officer, who will remain with the company in his current position until July 15, 2022. The Company has initiated a comprehensive search with the assistance of a leading executive search firm to identify a successor for this position.

PERRIGO ANNOUNCES CFO RETIREMENT AND TRANSITION PLAN

DUBLIN , March 17, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for the over-the-counter use of Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg). This approval marks the first branded Rx-to-OTC switch for the Company and paves the way for Nasonex® to enter the OTC marketplace.

PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OTC USE OF NASONEX® 24HR ALLERGY

DUBLIN, March 10, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Quality Affordable Self-Care Products, today announced that it has completed the previously announced sale of its Mexico and Brazil-based over-the-counter (OTC) businesses to Advent International. This transaction is part of Perrigo's margin improvement program and Project Momentum cost savings initiative.

PERRIGO COMPLETES DIVESTITURE OF LATIN AMERICAN BUSINESSES

The company recovered nicely from the challenges of the coronavirus pandemic, as indicated by its Q4 results.

Why Perrigo Stock Bounced Higher Today

Perrigo Company plc (PRGO) CEO Murray Kessler on Q4 2021 results - Earnings Call Transcript

Perrigo (PRGO) reports encouraging fourth-quarter 2021 results. Sales of cough/cold products continue the strong rebound during the reported quarter.

Perrigo (PRGO) Q4 Earnings Beat as Cough & Cold Sales Recover

Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Beats Q4 Earnings and Revenue Estimates

Shares of Perrigo Co. PRGO, -0.45% gained 2.7% in premarket trading on Tuesday after the drug maker beat on earnings expectations for the final three months of the year. Perrigo had net income of $32.1 million, or 24 cents per share, in the fourth quarter of 2021.

Perrigo's stock gains 2.7% on fourth-quarter earnings

DUBLIN, March 1, 2022 /PRNewswire/ -- Highlights: Fourth quarter net sales grew 4.9%, or 5.7% excluding the impact of currency, compared to the prior year to $1.1 billion led by a strong rebound in the demand for cough/cold products. Fiscal year 2021 net sales increased 1.2%, or down 0.3% excluding the impact of currency, to $4.1 billion, including a negative impact of 1.7 percentage points from lower net sales of cough/cold products worldwide during the year.

PERRIGO REPORTS FOURTH QUARTER & FISCAL YEAR 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS

Perrigo Company plc (NYSE: PRGO) Q4 FY21 sales increased 4.9% Y/Y to $1.1 billion, in line with the consensus of $1.10 billion, led by a strong rebound in demand for cough/cold products. Acquisitions accounted for 0.2% growth points, while unfavorable currency movements offset growth by.

Perrigo Clocks 5% Sales Growth In Q4, Bottom-Line Surpass Expectation

DUBLIN, Feb. 25, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) today announced that President and CEO, Murray S. Kessler and CFO Ray Silcock are scheduled to present at the Raymond James 43rd Annual Institutional Investors Conference at 11:00 AM EST on Tuesday, March 8th in Orlando, Florida.

PERRIGO TO PRESENT AT UPCOMING INVESTOR CONFERENCES

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Is a Beat Likely for Perrigo (PRGO) This Earnings Season?

DUBLIN, Feb. 15, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and fiscal year 2021 financial results on Tuesday, March 1, 2022. The Company will also host a conference call beginning at 8:30 A.M.

PERRIGO TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ON MARCH 1, 2022

Perrigo (PRGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Perrigo (PRGO) a New Buy Stock

After losing some value lately, a hammer chart pattern has been formed for Perrigo (PRGO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

News for Perrigo Stock (PRGO)